Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: MEN 11420

Latest Information Update: 28 Jul 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Menarini
  • Class Antiasthmatics; Antispasmodics; Cyclic peptides; Irritable bowel syndrome therapies
  • Mechanism of Action Neurokinin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Colic; Gastrointestinal disorders; Postoperative ileus

Most Recent Events

  • 28 Jul 2017 Discontinued - Phase-II for Colic (In infants) in USA, Sweden, Poland, Germany, and Italy (PO), because Nepadutant was not listed on Menarini pipeline, July 2017
  • 02 Jun 2015 Phase II development in Colic (infants) is ongoing in USA, Sweden, Poland, Germany and Italy
  • 15 Nov 2010 Phase-II clinical trials in Colic in infants in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top